Tango Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€20.85M - Cost of goods sold
€536.25K - Gross profit
€20.31M - SG&A expenses
€38.72M - R&D expenses
€116.54M - EBITDA
-€130.97M - D&A
€2.14M - EBIT
-€134.95M - Interest expenses
€0.00 - EBT
-€124.75M - Tax expenses
€147.58K - Net income
-€124.90M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€12.63M - Changes in working capital
-€16.24M - Operating cash flow
-€127.20M - Capex
€784.21K - Other investing cash flow
€0.00 - Net investing cash flow
€113.26M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€0.00 - Other financing cash flow
€3.39M - Net financing cash flow
€3.39M - Foreign exchange effects
€0.00 - Net change in cash
-€10.55M - Cash at end of period
€35.90M - Free cash flow
-€126.42M
Balance sheet
- Cash and cash equivalents
€34.06M - Cash and short-term investments
€155.48M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€7.63M - Total current assets
€163.11M - Property, plant & equipment
€38.90M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.84M - Other non-current assets
€265.98K - Total non-current assets
€41.00M - Total assets
€204.11M - Accounts payable
€2.24M - Short-term debt
€2.17M - Other current liabilities
€9.88M - Total current liabilities
€34.34M - Long-term debt
€55.73M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€53.98M - Total liabilities
€88.32M - Common stock
€95.24K - Retained earnings
-€497.89M - Other equity
€80.65K - Total equity
€115.79M - Total liabilities and shareholders' equity
€204.11M
Company information
- Market capitalization
€463.20M - Employees
155 - Enterprise Value
€492.30M
Company ratios
- Gross margin
-
97.4% Much better than peer group: -688.3% - EBITDA margin
-
-628.3% Much better than peer group: -5,441.7% - EBIT margin
-
-647.3% Much better than peer group: -5,805.3% - EBT margin
-
-598.4% Much better than peer group: -5,472.3% - Net margin
-
-599.1% Much better than peer group: -5,369.5% - ROE
-
-107.9% Much better than peer group: -260.0% - ROA
-
-61.2% Much worse than peer group: -34.1% - Asset turnover
-
10.2% Better than peer group: 4.3% - FCF margin
-
-613.9% Much better than peer group: -4,482.6% - FCF yield
-27.6% - Efficiency ratio
728.3% - Net sales per employee
-
€134.50K - Net income per employee
-
-€805.78K